NCT00375128

CompletedPhase 1/2

Sporozoite Challenge of Polyprotein Vaccinees

European Vaccine Initiative Source

Compare

Other study identifiers

Sponsor study identifier

VAC027.2

Secondary identifiers

EudraCT number: 2006-000629-67

EMVI trial identifier: PP_2_04

Study Type

interventional

Reported enrollment (type unavailable)

26

Locations

1 country

Sites

2

Timeline

Study Start

September 2006

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

April 2007

Actual (reported)

Brief Summary

This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite. Volunteers for this trial will have received these vaccines in the preceding trial VAC027.1.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): 26 participants
Study completion date: April 2007
Actual (reported)
Listed locations: 1 countries · 2 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
September 2006
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 10, 2006
Actual (reported)
First Posted
September 12, 2006
Actual (reported)
Study Completion
April 2007
Actual (reported)

Last Updated: October 19, 2007
Status Verified: October 2007
Last Update Submitted: October 18, 2007

Conditions

Malaria Malaria, Falciparum

Keywords

MalariaVaccinePrime-boostChallenge

Outcome Measures

Primary Outcomes (1)

Efficacy (time in hours to parasitaemia)

Secondary Outcomes (1)

Immunogenicity

Interventions

FP9-PP (FP9 polyprotein)Biological

MVA-PP (Modified Virus Ankara polyprotein)Biological

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 50 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Healthy non-pregnant adults aged 18 to 50 years
The vaccinated group will be subjects who have received the vaccine regime described for group 6 or 7 in VAC027.1

Sponsors & Collaborators

Walter Reed Army Institute of Research (WRAIR)
US federal agencycollaborator
European Vaccine Initiative
Otherlead
Wellcome Trust

Study Sites (2)

Imperial College, University of London

London, SW7 2AZ, United Kingdom

Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford

Oxford, OX3 7LJ, United Kingdom

MeSH Terms

Conditions

Malaria, FalciparumMalaria

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Study Officials

Adrian VS Hill, MA, BM BCh, DPhil, DM
University of Oxford
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 1 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: PREVENTION
Intervention Model: PARALLEL
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 10, 2006

First Posted

September 12, 2006

Study Start

September 2006

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

April 2007

Actual (reported)

NCT00890760

A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites

Phase 1/2Completed

NCT00385047

A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults

Phase 1/2Completed

NCT01142765

Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP

Phase 1/2Completed

NCT02252640

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Phase 1/2Completed

NCT00984763

A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria

Phase 1/2Completed

NCT01623557

A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates

Phase 1/2Completed

Resident in or near Oxford, UK for the duration of the challenge study

For females only, willingness to practice effective contraception during the challenge study.

Agreement to refrain from blood donation during the course of the study

Written informed consent

Willingness to allow the investigators to access hospital and General Practitioner medical notes

Willingness to undergo an HIV test

You may not qualify if:

Any deviation from the protocol-defined normal range in biochemistry or haematology blood tests or in urine analysis
Prior receipt of an investigational malaria vaccine (unless administered in VAC027.1)
Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period
Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination
History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet within 2 weeks prior to the challenge
Any history of malaria
Travel to a malaria endemic country within the previous 3 months prior to the planned challenge
Planned travel to malarious areas during the study period
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia
Evidence of cardiovascular disease
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
History of haemoglobinopathies
History of diabetes mellitus
Chronic or active neurological disease requiring ongoing specialist supervision
Chronic gastrointestinal disease requiring ongoing specialist supervision
+15 more criteria

Contact the study team to confirm eligibility.

Othercollaborator

University of Oxford

Othercollaborator

Last Updated

October 19, 2007

Record last verified: 2007-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00375128
Data provider: ClinicalTrials.gov
Source updated: 2007-10-19
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:25:12 UTC

Locations

GB(2)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations